December 11, 2023 Mendus announces positive survival data from Phase 2 ADVANCE II trial evaluating vididencel as maintenance therapy for AML at ASH 2023 Read more
December 6, 2023 Toleranzia reports positive feedback from meeting with the Danish Medicines Agency Read more
December 6, 2023 Mendus and Australasian Leukaemia & Lymphoma Group to expand clinical testing of vididencel as maintenance treatment for AML Read more
November 21, 2023 Xspray Pharma’s XS003 Achieves Superior Bioavailability Milestone, Matching TASIGNA® at Reduced Dosage Read more
November 10, 2023 Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan Read more
November 9, 2023 Xspray Pharma’s large shareholders and key individuals declare their intent to exercise TO5 warrants in November Read more
November 2, 2023 Prokarium Achieves Major Milestone with FDA’s IND Approval for Bladder Cancer Program Read more
October 17, 2023 Nanologica delivers silica to insulin manufacturer for evaluation in production Read more
October 16, 2023 KKR and Flerie Form Specialized Pharma Services Platform Frontier Biosolutions and Invest in Coriolis Pharma Read more
October 13, 2023 Xintela’s stem cell product, XSTEM, has been assessed as safe at all dose levels in knee osteoarthritis clinical study Read more
October 12, 2023 Synerkine Pharma secures €12.1 million to accelerate novel pain therapeutics towards clinical proof-of-concept Read more
October 11, 2023 Egetis Therapeutics has secured approximately SEK 462 million in a combined financing comprising a SEK 172 million equity private placement and SEK 290 million debt financing Read more
October 9, 2023 Egetis submits marketing authorisation application for Emcitate for treatment of MCT8 deficiency to the European Medicines Agency Read more
September 28, 2023 Geneos Therapeutics Closes its Series A3 Financing With Investment of $5 Million Read more
September 13, 2023 A3P Biomedical and BioAgilytix enter partnership for Stockholm3 in the USA Read more
September 11, 2023 Xspray Pharma and Bristol Myers Squibb Reach Settlement on Dasynoc™ Patent Litigation, Paving Way for Early Market Launch Read more
September 8, 2023 Mendus receives U.S. FDA Fast Track Designation for vididencel in Acute Myeloid Leukemia (AML) Read more
August 31, 2023 Stockholm3 combines accurate diagnosis of prostate cancer with improved health economics Read more
